Our news journalists obtained a quote from the research from the Chonbuk National University School of Medicine, "Despite DM-associated ILD requires aggressive therapy with cytotoxic agents, the efficacy is questionable in some cases, and more effective and less toxic therapies are needed. Recently, although there have been several reports of successful treatment of refractory case of PM and DM with the TNF-a antagonists, including infliximab and etanercept, there was no enough evidence for DM-associated ILD."
According to the news editors, the research concluded: "We described herein a patient with DM-associated ILD who had poor response to conventional therapies and successfully treated with adalimumab."
For more information on this research see: Successful treatment for conventional treatment-resistant dermatomyositis-associated interstitial lung disease with adalimumab. Rheumatology International, 2012;32(11):3587-90. Rheumatology International can be contacted at: Springer, 233 Spring Street, New York, NY 10013, USA. (Springer - www.springer.com; Rheumatology International - www.springerlink.com/content/0172-8172/)
Our news journalists report that additional information may be obtained by contacting J.K. Park, Division of Rheumatology, Dept. of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine, San 2-20 Geumam-dong, Deokjin-gu, Jeonju, Jeonbuk, 561-180, South Korea.
Publisher contact information for the journal Rheumatology International is: Springer, 233 Spring Street, New York, NY 10013, USA.
Keywords for this news article include: Asia, Antirheumatics, Pharmaceuticals, Drugs, Jeonbuk, Therapy, Adalimumab, South Korea, Polymyositis, Rheumatology, Dermatomyositis, Muscular Diseases, Immunologic Agents, Monoclonal Antibodies, Musculoskeletal Diseases, Interstitial Lung Disease, Respiratory Tract Diseases, Skin Diseases and Conditions.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2012, NewsRx LLC
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.